Research Analysts’ Weekly Ratings Updates for Relay Therapeutics (RLAY)

Several brokerages have updated their recommendations and price targets on shares of Relay Therapeutics (NASDAQ: RLAY) in the last few weeks:

• 4/29/2026 – Relay Therapeutics had its price target raised by HC Wainwright from $19.00 to $25.00. They now have a “buy” rating on the stock.
• 4/28/2026 – Relay Therapeutics had its price target raised by Oppenheimer Holdings, Inc. from $14.00 to $18.00. They now have an “outperform” rating on the stock.
• 4/28/2026 – Relay Therapeutics had its price target raised by Wells Fargo & Company from $17.00 to $21.00. They now have an “overweight” rating on the stock.
• 4/28/2026 – Relay Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $13.00 to $22.00. They now have a “buy” rating on the stock.
• 4/28/2026 – Relay Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
• 4/28/2026 – Relay Therapeutics had its price target raised by Citizens Jmp from $17.00 to $19.00. They now have a “market outperform” rating on the stock.
• 4/14/2026 – Relay Therapeutics is now covered by JonesTrading. They set a “hold” rating and a $18.00 price target on the stock.
• 4/8/2026 – Relay Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/8/2026 – Relay Therapeutics had its price target raised by Barclays PLC from $17.00 to $21.00. They now have an “overweight” rating on the stock.
• 3/23/2026 – Relay Therapeutics had its price target raised by HC Wainwright from $14.00 to $19.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Relay Therapeutics had its price target raised by Citizens Jmp from $15.00 to $17.00. They now have a “market outperform” rating on the stock.
• 3/17/2026 – Relay Therapeutics had its price target raised by Wells Fargo & Company from $15.00 to $17.00. They now have an “overweight” rating on the stock.
• 3/16/2026 – Relay Therapeutics had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 3/13/2026 – Relay Therapeutics had its price target raised by Guggenheim from $15.00 to $22.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In related news, CFO Thomas Catinazzo sold 1,800 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $15.00, for a total value of $27,000.00. Following the sale, the chief financial officer directly owned 213,867 shares in the company, valued at $3,208,005. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 22,732 shares of company stock valued at $305,048. 4.32% of the stock is owned by company insiders.

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.